Xenogeneic-free generation of vascular smooth muscle cells from human induced pluripotent stem cells for vascular tissue engineering

被引：11

作者：

Luo, Jiesi ^{[1
,2
]}

Lin, Yuyao ^{[1
,2
,3
]}

Shi, Xiangyu ^{[1
,2
,4
]}

Li, Guangxin ^{[5
,6
]}

Kural, Mehmet H. ^{[7
,8
]}

Anderson, Christopher W. ^{[1
,2
,7
,9
]}

Ellis, Matthew W. ^{[1
,2
,10
]}

Riaz, Muhammad ^{[1
,2
]}

Tellides, George ^{[5
,7
]}

Niklason, Laura E. ^{[2
,5
,7
,8
]}

Qyang, Yibing ^{[1
,2
,7
,9
]}

机构：

[1] Yale Cardiovasc Res Ctr, Yale Sch Med, Sect Cardiovasc Med, Dept Internal Med, New Haven, CT 06511 USA

[2] Yale Stem Cell Ctr, New Haven, CT 06520 USA

[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Cardiovasc Med, Xian 710061, Shaanxi, Peoples R China

[4] Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Changsha 410011, Hunan, Peoples R China

[5] Yale Univ, Dept Surg, New Haven, CT 06520 USA

[6] China Med Univ, Hosp 1, Dept Vasc Surg, Shenyang 110122, Peoples R China

[7] Yale Univ, Vasc Biol & Therapeut Program, Sch Med, New Haven, CT 06520 USA

[8] Yale Univ, Dept Anesthesiol, New Haven, CT 06519 USA

[9] Yale Sch Med, Dept Pathol, New Haven, CT 06520 USA

[10] Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06519 USA

来源：

ACTA BIOMATERIALIA | 2021年 / 119卷

关键词：

Human induced pluripotent stem cells; vascular smooth muscle cells; xenogeneic-free; vascular tissue engineering; GROWTH-FACTOR-BETA; HUMAN FIBROBLASTS; SYNTHETIC GRAFT; IN-VITRO; VESSELS; SERUM; DERIVATION; INHIBITION; ANTIBODIES; SUBTYPES;

D O I：

10.1016/j.actbio.2020.10.042

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Development of mechanically advanced tissue-engineered vascular grafts (TEVGs) from human induced pluripotent stem cell (hiPSC)-derived vascular smooth muscle cells (hiPSC-VSMCs) offers an innovative approach to replace or bypass diseased blood vessels. To move current hiPSC-TEVGs toward clinical application, it is essential to obtain hiPSC-VSMC-derived tissues under xenogeneic-free conditions, meaning without the use of any animal-derived reagents. Many approaches in VSMC differentiation of hiPSCs have been reported, although a xenogeneic-free method for generating hiPSC-VSMCs suitable for vascular tissue engineering has yet to be established. Based on our previously established standard method of xenogeneic VSMC differentiation, we have replaced all animal-derived reagents with functional counterparts of human origin and successfully derived functional xenogeneic-free hiPSC-VSMCs (XF-hiPSC-VSMCs). Next, our group developed tissue rings via cellular self-assembly from XF-hiPSC-VSMCs, which exhibited comparable mechanical strength to those developed from xenogeneic hiPSC-VSMCs. Moreover, by seeding XF-hiPSC-VSMCs onto biodegradable polyglycolic acid (PGA) scaffolds, we generated engineered vascular tissues presenting effective collagen deposition which were suitable for implantation into an immunodeficient mice model. In conclusion, our xenogeneic-free conditions for generating hiPSC-VSMCs produce cells with the comparable capacity for vascular tissue engineering as standard xenogeneic protocols, thereby moving the hiPSC-TEVG technology one step closer to safe and efficacious clinical translation. (C) 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

引用

页码：155 / 168

页数：14

共 61 条

[51] Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension [J].